Chemical Drugs

Chemical Drugs Comprehensive Study by Application (Cardiovascular Diseases, Diabetes, Central Nervous System Disorders, Respiratory Diseases, Infectious Diseases, Autoimmune Diseases), Route of Administration (Oral Drugs, Injectable Drugs, Topical Drugs, Ocular Drugs, Pulmonary Drugs, Nasal Drugs, Trans mucosal Drugs, Implantable Drugs, Others), End User (Hospitals, Ambulatory Surgery Centres/Clinics, Home Care Settings, Diagnostic Centres, Others) Players and Region - Global Market Outlook to 2027

Chemical Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Chemical Drugs Market Overview:
Chemical drugs do have low molecular weight and are created using a process called chemical synthesis, which starts with substances that, under specific circumstances, transform into molecules that have pharmacological activity. In general, the medicine has a detailed chemical description and is used with a dosage specified in terms of weight. Increasing use of pharmaceutical active ingredients by several pharmaceutical companies, and rising government support for the innovation in pharmaceutical industries are some factors that are driving the market.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increasing Use of Pharmaceutical Active Ingredients by Several Pharmaceutical Companies, Rising Government Support for the Innovation in Pharmaceutical Industries, Improving excipient capabilities using nanotechnology and Increasing use of direct compression in oral dosage formulations

Market Growth Drivers:
Growing Demand for Chemical Drugs, Increasing Use of Generic Drugs Coupled With Presence of a Large Number of Multinational Pharmaceutical, Technological advancements and new product launches and Increasing investments in R&D of Chemical Drugs

Challenges:
Safety and quality concerns and Changing trade policies

Restraints:
Stringent Environmental Regulation, High Cost of Raw Materials and Cost and time-intensive drug development process

Opportunities:
Cost Effective Production Environment of Pharmaceutical Ingredients in Emerging Nations, Self-administration and home care and Rising demand for biosimilar and biologics

Competitive Landscape:
Global chemical drugs is a fragmented market due to the presence of various players. The players are focusing on strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.
Some of the key players profiled in the report are Johnson & Johnson (United States), Pfizer (United States), Roche (Switzerland), Novartis (Switzerland), Merck & Co. (United States), Sanofi (France), AbbVie (United States), Orchid Chemicals & Pharmaceuticals (India), J.B.Chemicals and Pharmaceuticals Ltd. (India), North China Pharmaceutical Group Corporation (China), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom) and Cipla (India). Additionally, following companies can also be profiled that are part of our coverage like Northeast Pharmaceutical Group Co. (China), Zhejiang Medicine Co., Ltd. (China), Hoffmann-La Roche (Switzerland), Abbott Laboratories (United States) and Eli Lilly and Company (United States). Considering Market by Route of Administration, the sub-segment i.e. Oral Drugs will boost the Chemical Drugs market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Chemical Drugs market.

Latest Market Insights:
In June 2022, Board of Directors of JB Chemicals & Pharmaceuticals had approved a proposal to acquire four paediatric brands from Dr Reddy's Laboratories for about USD 12.3 million.

In May 2022, Takeda Pharmaceuticals Co Ltd launched the Adynovate drug. It is used for hemophilia treatment. It offers effective bleed resolution with closer-to-zero spontaneous bleed, better joint health, and reduced infusion and associated pain.

What Can be Explored with the Chemical Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Chemical Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Chemical Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Chemical Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Chemical Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Chemical Drugs Manufacturers, Chemical Drugs Suppliers, Regulatory Bodies, Potential Investors, Research and Development Institutes, End User and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Cardiovascular Diseases
  • Diabetes
  • Central Nervous System Disorders
  • Respiratory Diseases
  • Infectious Diseases
  • Autoimmune Diseases
By Route of Administration
  • Oral Drugs
  • Injectable Drugs
  • Topical Drugs
  • Ocular Drugs
  • Pulmonary Drugs
  • Nasal Drugs
  • Trans mucosal Drugs
  • Implantable Drugs
  • Others

By End User
  • Hospitals
  • Ambulatory Surgery Centres/Clinics
  • Home Care Settings
  • Diagnostic Centres
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand for Chemical Drugs
      • 3.2.2. Increasing Use of Generic Drugs Coupled With Presence of a Large Number of Multinational Pharmaceutical
      • 3.2.3. Technological advancements and new product launches
      • 3.2.4. Increasing investments in R&D of Chemical Drugs
    • 3.3. Market Challenges
      • 3.3.1. Safety and quality concerns
      • 3.3.2. Changing trade policies
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Pharmaceutical Active Ingredients by Several Pharmaceutical Companies
      • 3.4.2. Rising Government Support for the Innovation in Pharmaceutical Industries
      • 3.4.3. Improving excipient capabilities using nanotechnology
      • 3.4.4. Increasing use of direct compression in oral dosage formulations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chemical Drugs, by Application, Route of Administration, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Chemical Drugs (Value)
      • 5.2.1. Global Chemical Drugs by: Application (Value)
        • 5.2.1.1. Cardiovascular Diseases
        • 5.2.1.2. Diabetes
        • 5.2.1.3. Central Nervous System Disorders
        • 5.2.1.4. Respiratory Diseases
        • 5.2.1.5. Infectious Diseases
        • 5.2.1.6. Autoimmune Diseases
      • 5.2.2. Global Chemical Drugs by: Route of Administration (Value)
        • 5.2.2.1. Oral Drugs
        • 5.2.2.2. Injectable Drugs
        • 5.2.2.3. Topical Drugs
        • 5.2.2.4. Ocular Drugs
        • 5.2.2.5. Pulmonary Drugs
        • 5.2.2.6. Nasal Drugs
        • 5.2.2.7. Trans mucosal Drugs
        • 5.2.2.8. Implantable Drugs
        • 5.2.2.9. Others
      • 5.2.3. Global Chemical Drugs by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgery Centres/Clinics
        • 5.2.3.3. Home Care Settings
        • 5.2.3.4. Diagnostic Centres
        • 5.2.3.5. Others
      • 5.2.4. Global Chemical Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Chemical Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Orchid Chemicals & Pharmaceuticals (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. J.B.Chemicals and Pharmaceuticals Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. North China Pharmaceutical Group Corporation (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GlaxoSmithKline (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. AstraZeneca (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Cipla (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Chemical Drugs Sale, by Application, Route of Administration, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Chemical Drugs (Value)
      • 7.2.1. Global Chemical Drugs by: Application (Value)
        • 7.2.1.1. Cardiovascular Diseases
        • 7.2.1.2. Diabetes
        • 7.2.1.3. Central Nervous System Disorders
        • 7.2.1.4. Respiratory Diseases
        • 7.2.1.5. Infectious Diseases
        • 7.2.1.6. Autoimmune Diseases
      • 7.2.2. Global Chemical Drugs by: Route of Administration (Value)
        • 7.2.2.1. Oral Drugs
        • 7.2.2.2. Injectable Drugs
        • 7.2.2.3. Topical Drugs
        • 7.2.2.4. Ocular Drugs
        • 7.2.2.5. Pulmonary Drugs
        • 7.2.2.6. Nasal Drugs
        • 7.2.2.7. Trans mucosal Drugs
        • 7.2.2.8. Implantable Drugs
        • 7.2.2.9. Others
      • 7.2.3. Global Chemical Drugs by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgery Centres/Clinics
        • 7.2.3.3. Home Care Settings
        • 7.2.3.4. Diagnostic Centres
        • 7.2.3.5. Others
      • 7.2.4. Global Chemical Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chemical Drugs: by Application(USD Million)
  • Table 2. Chemical Drugs Cardiovascular Diseases , by Region USD Million (2016-2021)
  • Table 3. Chemical Drugs Diabetes , by Region USD Million (2016-2021)
  • Table 4. Chemical Drugs Central Nervous System Disorders , by Region USD Million (2016-2021)
  • Table 5. Chemical Drugs Respiratory Diseases , by Region USD Million (2016-2021)
  • Table 6. Chemical Drugs Infectious Diseases , by Region USD Million (2016-2021)
  • Table 7. Chemical Drugs Autoimmune Diseases , by Region USD Million (2016-2021)
  • Table 8. Chemical Drugs: by Route of Administration(USD Million)
  • Table 9. Chemical Drugs Oral Drugs , by Region USD Million (2016-2021)
  • Table 10. Chemical Drugs Injectable Drugs , by Region USD Million (2016-2021)
  • Table 11. Chemical Drugs Topical Drugs , by Region USD Million (2016-2021)
  • Table 12. Chemical Drugs Ocular Drugs , by Region USD Million (2016-2021)
  • Table 13. Chemical Drugs Pulmonary Drugs , by Region USD Million (2016-2021)
  • Table 14. Chemical Drugs Nasal Drugs , by Region USD Million (2016-2021)
  • Table 15. Chemical Drugs Trans mucosal Drugs , by Region USD Million (2016-2021)
  • Table 16. Chemical Drugs Implantable Drugs , by Region USD Million (2016-2021)
  • Table 17. Chemical Drugs Others , by Region USD Million (2016-2021)
  • Table 18. Chemical Drugs: by End User(USD Million)
  • Table 19. Chemical Drugs Hospitals , by Region USD Million (2016-2021)
  • Table 20. Chemical Drugs Ambulatory Surgery Centres/Clinics , by Region USD Million (2016-2021)
  • Table 21. Chemical Drugs Home Care Settings , by Region USD Million (2016-2021)
  • Table 22. Chemical Drugs Diagnostic Centres , by Region USD Million (2016-2021)
  • Table 23. Chemical Drugs Others , by Region USD Million (2016-2021)
  • Table 24. South America Chemical Drugs, by Country USD Million (2016-2021)
  • Table 25. South America Chemical Drugs, by Application USD Million (2016-2021)
  • Table 26. South America Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 27. South America Chemical Drugs, by End User USD Million (2016-2021)
  • Table 28. Brazil Chemical Drugs, by Application USD Million (2016-2021)
  • Table 29. Brazil Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 30. Brazil Chemical Drugs, by End User USD Million (2016-2021)
  • Table 31. Argentina Chemical Drugs, by Application USD Million (2016-2021)
  • Table 32. Argentina Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 33. Argentina Chemical Drugs, by End User USD Million (2016-2021)
  • Table 34. Rest of South America Chemical Drugs, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 36. Rest of South America Chemical Drugs, by End User USD Million (2016-2021)
  • Table 37. Asia Pacific Chemical Drugs, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Chemical Drugs, by Application USD Million (2016-2021)
  • Table 39. Asia Pacific Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 40. Asia Pacific Chemical Drugs, by End User USD Million (2016-2021)
  • Table 41. China Chemical Drugs, by Application USD Million (2016-2021)
  • Table 42. China Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 43. China Chemical Drugs, by End User USD Million (2016-2021)
  • Table 44. Japan Chemical Drugs, by Application USD Million (2016-2021)
  • Table 45. Japan Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 46. Japan Chemical Drugs, by End User USD Million (2016-2021)
  • Table 47. India Chemical Drugs, by Application USD Million (2016-2021)
  • Table 48. India Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 49. India Chemical Drugs, by End User USD Million (2016-2021)
  • Table 50. South Korea Chemical Drugs, by Application USD Million (2016-2021)
  • Table 51. South Korea Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 52. South Korea Chemical Drugs, by End User USD Million (2016-2021)
  • Table 53. Taiwan Chemical Drugs, by Application USD Million (2016-2021)
  • Table 54. Taiwan Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 55. Taiwan Chemical Drugs, by End User USD Million (2016-2021)
  • Table 56. Australia Chemical Drugs, by Application USD Million (2016-2021)
  • Table 57. Australia Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 58. Australia Chemical Drugs, by End User USD Million (2016-2021)
  • Table 59. Rest of Asia-Pacific Chemical Drugs, by Application USD Million (2016-2021)
  • Table 60. Rest of Asia-Pacific Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Chemical Drugs, by End User USD Million (2016-2021)
  • Table 62. Europe Chemical Drugs, by Country USD Million (2016-2021)
  • Table 63. Europe Chemical Drugs, by Application USD Million (2016-2021)
  • Table 64. Europe Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 65. Europe Chemical Drugs, by End User USD Million (2016-2021)
  • Table 66. Germany Chemical Drugs, by Application USD Million (2016-2021)
  • Table 67. Germany Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 68. Germany Chemical Drugs, by End User USD Million (2016-2021)
  • Table 69. France Chemical Drugs, by Application USD Million (2016-2021)
  • Table 70. France Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 71. France Chemical Drugs, by End User USD Million (2016-2021)
  • Table 72. Italy Chemical Drugs, by Application USD Million (2016-2021)
  • Table 73. Italy Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 74. Italy Chemical Drugs, by End User USD Million (2016-2021)
  • Table 75. United Kingdom Chemical Drugs, by Application USD Million (2016-2021)
  • Table 76. United Kingdom Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 77. United Kingdom Chemical Drugs, by End User USD Million (2016-2021)
  • Table 78. Netherlands Chemical Drugs, by Application USD Million (2016-2021)
  • Table 79. Netherlands Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 80. Netherlands Chemical Drugs, by End User USD Million (2016-2021)
  • Table 81. Rest of Europe Chemical Drugs, by Application USD Million (2016-2021)
  • Table 82. Rest of Europe Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 83. Rest of Europe Chemical Drugs, by End User USD Million (2016-2021)
  • Table 84. MEA Chemical Drugs, by Country USD Million (2016-2021)
  • Table 85. MEA Chemical Drugs, by Application USD Million (2016-2021)
  • Table 86. MEA Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 87. MEA Chemical Drugs, by End User USD Million (2016-2021)
  • Table 88. Middle East Chemical Drugs, by Application USD Million (2016-2021)
  • Table 89. Middle East Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 90. Middle East Chemical Drugs, by End User USD Million (2016-2021)
  • Table 91. Africa Chemical Drugs, by Application USD Million (2016-2021)
  • Table 92. Africa Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 93. Africa Chemical Drugs, by End User USD Million (2016-2021)
  • Table 94. North America Chemical Drugs, by Country USD Million (2016-2021)
  • Table 95. North America Chemical Drugs, by Application USD Million (2016-2021)
  • Table 96. North America Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 97. North America Chemical Drugs, by End User USD Million (2016-2021)
  • Table 98. United States Chemical Drugs, by Application USD Million (2016-2021)
  • Table 99. United States Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 100. United States Chemical Drugs, by End User USD Million (2016-2021)
  • Table 101. Canada Chemical Drugs, by Application USD Million (2016-2021)
  • Table 102. Canada Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 103. Canada Chemical Drugs, by End User USD Million (2016-2021)
  • Table 104. Mexico Chemical Drugs, by Application USD Million (2016-2021)
  • Table 105. Mexico Chemical Drugs, by Route of Administration USD Million (2016-2021)
  • Table 106. Mexico Chemical Drugs, by End User USD Million (2016-2021)
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Chemical Drugs: by Application(USD Million)
  • Table 121. Chemical Drugs Cardiovascular Diseases , by Region USD Million (2022-2027)
  • Table 122. Chemical Drugs Diabetes , by Region USD Million (2022-2027)
  • Table 123. Chemical Drugs Central Nervous System Disorders , by Region USD Million (2022-2027)
  • Table 124. Chemical Drugs Respiratory Diseases , by Region USD Million (2022-2027)
  • Table 125. Chemical Drugs Infectious Diseases , by Region USD Million (2022-2027)
  • Table 126. Chemical Drugs Autoimmune Diseases , by Region USD Million (2022-2027)
  • Table 127. Chemical Drugs: by Route of Administration(USD Million)
  • Table 128. Chemical Drugs Oral Drugs , by Region USD Million (2022-2027)
  • Table 129. Chemical Drugs Injectable Drugs , by Region USD Million (2022-2027)
  • Table 130. Chemical Drugs Topical Drugs , by Region USD Million (2022-2027)
  • Table 131. Chemical Drugs Ocular Drugs , by Region USD Million (2022-2027)
  • Table 132. Chemical Drugs Pulmonary Drugs , by Region USD Million (2022-2027)
  • Table 133. Chemical Drugs Nasal Drugs , by Region USD Million (2022-2027)
  • Table 134. Chemical Drugs Trans mucosal Drugs , by Region USD Million (2022-2027)
  • Table 135. Chemical Drugs Implantable Drugs , by Region USD Million (2022-2027)
  • Table 136. Chemical Drugs Others , by Region USD Million (2022-2027)
  • Table 137. Chemical Drugs: by End User(USD Million)
  • Table 138. Chemical Drugs Hospitals , by Region USD Million (2022-2027)
  • Table 139. Chemical Drugs Ambulatory Surgery Centres/Clinics , by Region USD Million (2022-2027)
  • Table 140. Chemical Drugs Home Care Settings , by Region USD Million (2022-2027)
  • Table 141. Chemical Drugs Diagnostic Centres , by Region USD Million (2022-2027)
  • Table 142. Chemical Drugs Others , by Region USD Million (2022-2027)
  • Table 143. South America Chemical Drugs, by Country USD Million (2022-2027)
  • Table 144. South America Chemical Drugs, by Application USD Million (2022-2027)
  • Table 145. South America Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 146. South America Chemical Drugs, by End User USD Million (2022-2027)
  • Table 147. Brazil Chemical Drugs, by Application USD Million (2022-2027)
  • Table 148. Brazil Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 149. Brazil Chemical Drugs, by End User USD Million (2022-2027)
  • Table 150. Argentina Chemical Drugs, by Application USD Million (2022-2027)
  • Table 151. Argentina Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 152. Argentina Chemical Drugs, by End User USD Million (2022-2027)
  • Table 153. Rest of South America Chemical Drugs, by Application USD Million (2022-2027)
  • Table 154. Rest of South America Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 155. Rest of South America Chemical Drugs, by End User USD Million (2022-2027)
  • Table 156. Asia Pacific Chemical Drugs, by Country USD Million (2022-2027)
  • Table 157. Asia Pacific Chemical Drugs, by Application USD Million (2022-2027)
  • Table 158. Asia Pacific Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 159. Asia Pacific Chemical Drugs, by End User USD Million (2022-2027)
  • Table 160. China Chemical Drugs, by Application USD Million (2022-2027)
  • Table 161. China Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 162. China Chemical Drugs, by End User USD Million (2022-2027)
  • Table 163. Japan Chemical Drugs, by Application USD Million (2022-2027)
  • Table 164. Japan Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 165. Japan Chemical Drugs, by End User USD Million (2022-2027)
  • Table 166. India Chemical Drugs, by Application USD Million (2022-2027)
  • Table 167. India Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 168. India Chemical Drugs, by End User USD Million (2022-2027)
  • Table 169. South Korea Chemical Drugs, by Application USD Million (2022-2027)
  • Table 170. South Korea Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 171. South Korea Chemical Drugs, by End User USD Million (2022-2027)
  • Table 172. Taiwan Chemical Drugs, by Application USD Million (2022-2027)
  • Table 173. Taiwan Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 174. Taiwan Chemical Drugs, by End User USD Million (2022-2027)
  • Table 175. Australia Chemical Drugs, by Application USD Million (2022-2027)
  • Table 176. Australia Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 177. Australia Chemical Drugs, by End User USD Million (2022-2027)
  • Table 178. Rest of Asia-Pacific Chemical Drugs, by Application USD Million (2022-2027)
  • Table 179. Rest of Asia-Pacific Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 180. Rest of Asia-Pacific Chemical Drugs, by End User USD Million (2022-2027)
  • Table 181. Europe Chemical Drugs, by Country USD Million (2022-2027)
  • Table 182. Europe Chemical Drugs, by Application USD Million (2022-2027)
  • Table 183. Europe Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 184. Europe Chemical Drugs, by End User USD Million (2022-2027)
  • Table 185. Germany Chemical Drugs, by Application USD Million (2022-2027)
  • Table 186. Germany Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 187. Germany Chemical Drugs, by End User USD Million (2022-2027)
  • Table 188. France Chemical Drugs, by Application USD Million (2022-2027)
  • Table 189. France Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 190. France Chemical Drugs, by End User USD Million (2022-2027)
  • Table 191. Italy Chemical Drugs, by Application USD Million (2022-2027)
  • Table 192. Italy Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 193. Italy Chemical Drugs, by End User USD Million (2022-2027)
  • Table 194. United Kingdom Chemical Drugs, by Application USD Million (2022-2027)
  • Table 195. United Kingdom Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 196. United Kingdom Chemical Drugs, by End User USD Million (2022-2027)
  • Table 197. Netherlands Chemical Drugs, by Application USD Million (2022-2027)
  • Table 198. Netherlands Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 199. Netherlands Chemical Drugs, by End User USD Million (2022-2027)
  • Table 200. Rest of Europe Chemical Drugs, by Application USD Million (2022-2027)
  • Table 201. Rest of Europe Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 202. Rest of Europe Chemical Drugs, by End User USD Million (2022-2027)
  • Table 203. MEA Chemical Drugs, by Country USD Million (2022-2027)
  • Table 204. MEA Chemical Drugs, by Application USD Million (2022-2027)
  • Table 205. MEA Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 206. MEA Chemical Drugs, by End User USD Million (2022-2027)
  • Table 207. Middle East Chemical Drugs, by Application USD Million (2022-2027)
  • Table 208. Middle East Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 209. Middle East Chemical Drugs, by End User USD Million (2022-2027)
  • Table 210. Africa Chemical Drugs, by Application USD Million (2022-2027)
  • Table 211. Africa Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 212. Africa Chemical Drugs, by End User USD Million (2022-2027)
  • Table 213. North America Chemical Drugs, by Country USD Million (2022-2027)
  • Table 214. North America Chemical Drugs, by Application USD Million (2022-2027)
  • Table 215. North America Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 216. North America Chemical Drugs, by End User USD Million (2022-2027)
  • Table 217. United States Chemical Drugs, by Application USD Million (2022-2027)
  • Table 218. United States Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 219. United States Chemical Drugs, by End User USD Million (2022-2027)
  • Table 220. Canada Chemical Drugs, by Application USD Million (2022-2027)
  • Table 221. Canada Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 222. Canada Chemical Drugs, by End User USD Million (2022-2027)
  • Table 223. Mexico Chemical Drugs, by Application USD Million (2022-2027)
  • Table 224. Mexico Chemical Drugs, by Route of Administration USD Million (2022-2027)
  • Table 225. Mexico Chemical Drugs, by End User USD Million (2022-2027)
  • Table 226. Research Programs/Design for This Report
  • Table 227. Key Data Information from Secondary Sources
  • Table 228. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chemical Drugs: by Application USD Million (2016-2021)
  • Figure 5. Global Chemical Drugs: by Route of Administration USD Million (2016-2021)
  • Figure 6. Global Chemical Drugs: by End User USD Million (2016-2021)
  • Figure 7. South America Chemical Drugs Share (%), by Country
  • Figure 8. Asia Pacific Chemical Drugs Share (%), by Country
  • Figure 9. Europe Chemical Drugs Share (%), by Country
  • Figure 10. MEA Chemical Drugs Share (%), by Country
  • Figure 11. North America Chemical Drugs Share (%), by Country
  • Figure 12. Global Chemical Drugs share by Players 2021 (%)
  • Figure 13. Global Chemical Drugs share by Players (Top 3) 2021(%)
  • Figure 14. Global Chemical Drugs share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 17. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2021
  • Figure 20. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Roche (Switzerland) Revenue: by Geography 2021
  • Figure 22. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 24. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co. (United States) Revenue: by Geography 2021
  • Figure 26. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi (France) Revenue: by Geography 2021
  • Figure 28. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 29. AbbVie (United States) Revenue: by Geography 2021
  • Figure 30. Orchid Chemicals & Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 31. Orchid Chemicals & Pharmaceuticals (India) Revenue: by Geography 2021
  • Figure 32. J.B.Chemicals and Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 33. J.B.Chemicals and Pharmaceuticals Ltd. (India) Revenue: by Geography 2021
  • Figure 34. North China Pharmaceutical Group Corporation (China) Revenue, Net Income and Gross profit
  • Figure 35. North China Pharmaceutical Group Corporation (China) Revenue: by Geography 2021
  • Figure 36. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 38. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 40. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 41. Cipla (India) Revenue: by Geography 2021
  • Figure 42. Global Chemical Drugs: by Application USD Million (2022-2027)
  • Figure 43. Global Chemical Drugs: by Route of Administration USD Million (2022-2027)
  • Figure 44. Global Chemical Drugs: by End User USD Million (2022-2027)
  • Figure 45. South America Chemical Drugs Share (%), by Country
  • Figure 46. Asia Pacific Chemical Drugs Share (%), by Country
  • Figure 47. Europe Chemical Drugs Share (%), by Country
  • Figure 48. MEA Chemical Drugs Share (%), by Country
  • Figure 49. North America Chemical Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (United States)
  • Pfizer (United States)
  • Roche (Switzerland)
  • Novartis (Switzerland)
  • Merck & Co. (United States)
  • Sanofi (France)
  • AbbVie (United States)
  • Orchid Chemicals & Pharmaceuticals (India)
  • J.B.Chemicals and Pharmaceuticals Ltd. (India)
  • North China Pharmaceutical Group Corporation (China)
  • GlaxoSmithKline (United Kingdom)
  • AstraZeneca (United Kingdom)
  • Cipla (India)
Additional players considered in the study are as follows:
Northeast Pharmaceutical Group Co. (China) , Zhejiang Medicine Co., Ltd. (China) , Hoffmann-La Roche (Switzerland) , Abbott Laboratories (United States) , Eli Lilly and Company (United States)
Select User Access Type

Key Highlights of Report


Aug 2022 214 Pages 69 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Chemical Drugs Quantitative research analysis
Chemical Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Chemical Drugs market are Johnson & Johnson (United States), Pfizer (United States), Roche (Switzerland), Novartis (Switzerland), Merck & Co. (United States), Sanofi (France), AbbVie (United States), Orchid Chemicals & Pharmaceuticals (India), J.B.Chemicals and Pharmaceuticals Ltd. (India), North China Pharmaceutical Group Corporation (China), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom) and Cipla (India), to name a few.
"Increasing Use of Pharmaceutical Active Ingredients by Several Pharmaceutical Companies " is seen as one of major influencing trends for Chemical Drugs Market during projected period 2021-2027.

Know More About Chemical Drugs Report?

Have a Query? Click Here

Other Related Reports

Psychedelic Drugs Comprehensive Study by Application (Major Depressive Disorder, Resistant Depression, Panic Disorder, Post-traumatic Stress Disorder, Opiate Addiction, Others), Drug Type (Lysergic A...
$ 3750
Olanzapine Comprehensive Study by Type (Patent, Generics), Application (Schizophrenia, Bipolar Disorder, Other), Product Type (Tablet, Injection), Sales Channel (Online Pharmacy, Hospital Pharmacy, R...
$ 3350
Cephalexin Comprehensive Study by Type (Injection, Oral), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region -...
$ 3500
Mebendazole Comprehensive Study by Type (≥98%, ≥99%), End users (Below 2 Years Old, Above 2 Years 5Old), Form (Feed Additives, Tablet, Oral Suspension) Players and Region - Global Market ...
$ 3500
Pharmacy Benefit Management Services Comprehensive Study by Type (Commercial Health Plans, Self-Insured Employer Plans, Medicare Part D Plans, Federal Employees Health Benefits Program, State Governm...
$ 3750
Levonorgestrel API Comprehensive Study by Type (Innovative API, Generic API), Application (Birth Control, Hormone Therapy), Drugs Type (Prescription Drugs, Over-the-counter Drugs), Grade (BP (British...
$ 3650